Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 1-Year High – What’s Next?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares traded. The stock had previously closed at $52.25.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RCDTF. Barclays raised Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

The company has a market capitalization of $10.78 billion, a P/E ratio of 26.13 and a beta of 0.33. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The company’s fifty day moving average is $52.20 and its 200 day moving average is $52.03.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.